BUZZ-Tempest Therapeutics因合作伙伴资助的癌症新药计划而上涨

路透中文

Feb 11

BUZZ-Tempest <a href="https://laohu8.com/S/LENZ">Therapeutics</a>因合作伙伴资助的癌症新药计划而上涨

2月11日 - ** 癌症药物开发商 Tempest Therapeutics TPST.O股价盘前上涨 2.07% 至 2.47 美元

** 该公司表示，它将专注于开发新收购的癌症项目，同时通过合作伙伴资助的试验降低成本

** 该公司的TPST-2003是一种治疗血癌的双靶向CAR-T疗法，目前已在中国进行测试；预计将于2026年底进行更大规模的研究，并于2027年获得早期数据——该公司表示。

** 公司称 TPST-4003 旨在治疗癌症，无需复杂的细胞制造，计划在合作伙伴的支持下进入早期研究

** 2025 年股价下跌约 73%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610937323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610937323\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610937323?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-11 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610937323","market":"hk","top_or_hot":-1,"title":"BUZZ-Tempest Therapeutics因合作伙伴资助的癌症新药计划而上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>因合作伙伴资助的癌症新药计划而上涨</title></head><body><p><span>2月11日</span><span> - </span>** 癌症药物开发商 Tempest Therapeutics <span>TPST.O</span>股价盘前上涨 2.07% 至 2.47 美元</p><p>** 该公司表示，它将专注于开发新收购的癌症项目，同时通过合作伙伴资助的试验降低成本</p><p>** 该公司的TPST-2003是一种治疗血癌的双靶向CAR-T疗法，目前已在中国进行测试；预计将于2026年底进行更大规模的研究，并于2027年获得早期数据——该公司表示。</p><p>** 公司称 TPST-4003 旨在治疗癌症，无需复杂的细胞制造，计划在合作伙伴的支持下进入早期研究</p><p>** 2025 年股价下跌约 73%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tempest Therapeutics因合作伙伴资助的癌症新药计划而上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tempest Therapeutics因合作伙伴资助的癌症新药计划而上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-02-11 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>因合作伙伴资助的癌症新药计划而上涨</title></head><body><p><span>2月11日</span><span> - </span>** 癌症药物开发商 Tempest Therapeutics <span>TPST.O</span>股价盘前上涨 2.07% 至 2.47 美元</p><p>** 该公司表示，它将专注于开发新收购的癌症项目，同时通过合作伙伴资助的试验降低成本</p><p>** 该公司的TPST-2003是一种治疗血癌的双靶向CAR-T疗法，目前已在中国进行测试；预计将于2026年底进行更大规模的研究，并于2027年获得早期数据——该公司表示。</p><p>** 公司称 TPST-4003 旨在治疗癌症，无需复杂的细胞制造，计划在合作伙伴的支持下进入早期研究</p><p>** 2025 年股价下跌约 73%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4T3Z7148:1","article_id":"2610937323","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610937323","pubTimestamp":1770813614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","TPST":"Tempest Therapeutics Inc."},"translate_title":"BUZZ-Tempest Therapeutics rises on partner-funded new cancer drug program","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":0.9},"content_text":"BUZZ-Tempest Therapeutics因合作伙伴资助的癌症新药计划而上涨2月11日 - ** 癌症药物开发商 Tempest Therapeutics TPST.O股价盘前上涨 2.07% 至 2.47 美元** 该公司表示，它将专注于开发新收购的癌症项目，同时通过合作伙伴资助的试验降低成本** 该公司的TPST-2003是一种治疗血癌的双靶向CAR-T疗法，目前已在中国进行测试；预计将于2026年底进行更大规模的研究，并于2027年获得早期数据——该公司表示。** 公司称 TPST-4003 旨在治疗癌症，无需复杂的细胞制造，计划在合作伙伴的支持下进入早期研究** 2025 年股价下跌约 73%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}